Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Roche
Biotech
89bio was left between a Roche and a hard place in buyout talks
Over three years, 89bio signed confidentiality agreements with 14 biopharmas as it advanced its MASH candidate.
Nick Paul Taylor
Oct 2, 2025 9:55am
Roche's obesity ambition not reliant on one megablockbuster
Sep 23, 2025 7:45am
Roche unveils strategy to become 'top 3' obesity company
Sep 22, 2025 8:05am
Roche reports phase 3 breast cancer victory for oral SERD
Sep 22, 2025 7:25am
What’s next for Roche’s expensive obesity pipeline?
Sep 19, 2025 10:16am
Roche becomes MASH player via $3.5B deal for 89bio, ph. 3 drug
Sep 18, 2025 5:02am
